Begin typing your search above and press return to search.
proflie-avatar
Login
exit_to_app
Kamala or Trump?
access_time 5 Nov 2024 4:05 AM GMT
Break up or get dissolved
access_time 4 Nov 2024 4:01 AM GMT
Through oneness to autocracy
access_time 2 Nov 2024 4:58 AM GMT
In football too racism rules the roost
access_time 1 Nov 2024 4:26 AM GMT
The concerns raised by the census
access_time 31 Oct 2024 7:49 AM GMT
exit_to_app
Homechevron_rightSportschevron_rightDjokovic, key...

Djokovic, key stakeholder in a firm developing Covid drug; says CEO

text_fields
bookmark_border
cancel
camera_alt""

A Danish biotech firm is developing a Covid therapy with tennis star Novak Djokovic as its founder and majority shareholder, the company's CEO announced Wednesday.

Djokovic was denied entry to Australia for violating the coronavirus vaccine law.

Ivan Loncarevic, the chief executive of QuantBioRes, said the company is developing a Covid treatment. "He is one of the founders of the company we founded in June 2020," he said.

A Danish business register shows Djokovic, 34, holds an 80 percent stake with his wife, Jelena, in QuantBioRes, which employs about 20 people in Denmark, Slovenia, Australia and Britain.

Loncarevic said, "We decided to develop Covid as a showcase. If we succeed with Covid, we will succeed with other viruses."

In a last-ditch attempt to stay and remain in Melbourne, the unvaccinated men's world number one had been denied a stay in the first grand slam of the year, where he was hoping to win a record 21st major title.

Clinical trials will begin at QuantBioRes in the UK in the summer, the CEO revealed.

In speaking to AFP, Djokovic's spokesman declined to comment on the tennis star's stake in the Danish biotech firm. This was the result of a long and high-profile legal battle between Djokovic and Australian authorities.


Show Full Article
TAGS:DjokovicCo-founderCovid therapy
Next Story